Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-07-11

FDA Approved: LEVOCETIRIZINE DIHYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Camber Pharmaceuticals' supplemental application for levocetirizine dihydrochloride, a generic antihistamine, under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Levocetirizine dihydrochloride (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

SUPPL AP for LEVOCETIRIZINE DIHYDROCHLORIDE (LEVOCETIRIZINE DIHYDROCHLORIDE)